Akums acquires Ankur Drugs’ plant in Himachal Pradesh

IMT News Desk
IMT News Desk
· 2 min read
Historic Deal Panacea Biotec & Serum Institute of India

The plan is that Ankur’s facility in Nalagarh in Solan, Himachal Pradesh, will boost Akums’ production capacities for general oral tablets and oral liquids by 6 billion units of tablets and 90 million units of oral liquids per annum

Akums Drugs & Pharmaceuticals has recently acquired a facility from Ankur Drugs and Pharmaceuticals. With this acquisition Akums’ will boost its production capacities for general oral tablets and oral liquids. The planned capacities of the new facility are six billion units of tablets and 90 million units of oral liquids per annum. This facility is most likely to be fully operational by the end of 2022.

Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, Sandeep Jain says, “What the addition of this new facility means to our existing network is to step up our continuous efforts to serve our customers efficiently and the nation better. We, at Akums, are already leading the market in many areas and, hence, we also know there is so much yet to be done. With this new facility in Nalagarh in Solan, Himachal Pradesh, we are trying to bridge some more capacity gaps in the pharma industry.” 

 Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, Shri Sanjeev Jain says, “In 2021, our supplies made up approximately 12 per cent of the total market. With this new facility acquisition in the state of Himachal Pradesh and our previous acquisition in Kotdwar, Uttarakhand, in August 2021, we have bolstered our total capacity further. This expansion is a step towards achieving our goal of 20 per cent market share. The operations at our Kotdwar plant have begun recently, while our new plant in Himachal Pradesh is likely to start its operations by December 2022.”

 

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk